Kura Oncology Inc (KURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kura Oncology Inc (KURA) has a cash flow conversion efficiency ratio of 0.673x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($117.27 Million) by net assets ($174.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kura Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Kura Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Kura Oncology Inc carry for a breakdown of total debt and financial obligations.
Kura Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kura Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ganesh Housing Corporation Limited
NSE:GANESHHOUC
|
0.199x |
|
Hangzhou Huasu Technology Co. Ltd. A
SHE:301157
|
N/A |
|
Zhejiang Wellsun Intelligent Tech
SHE:300882
|
0.112x |
|
Jiangxi Sanxin Medtec Co Ltd
SHE:300453
|
0.094x |
|
Ripley Corp
SN:RIPLEY
|
-0.017x |
|
Quidel Corporation
NASDAQ:QDEL
|
0.069x |
|
MBK Public Company Limited
BK:MBK-R
|
0.028x |
|
J Resources Asia Pasifik Tbk
JK:PSAB
|
0.139x |
Annual Cash Flow Conversion Efficiency for Kura Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see KURA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $174.13 Million | $-64.06 Million | -0.368x | -213.29% |
| 2024-12-31 | $413.64 Million | $134.32 Million | 0.325x | +203.35% |
| 2023-12-31 | $397.27 Million | $-124.82 Million | -0.314x | -19.98% |
| 2022-12-31 | $420.28 Million | $-110.06 Million | -0.262x | -26.90% |
| 2021-12-31 | $506.61 Million | $-104.55 Million | -0.206x | -80.55% |
| 2020-12-31 | $610.90 Million | $-69.83 Million | -0.114x | +54.33% |
| 2019-12-31 | $218.78 Million | $-54.76 Million | -0.250x | +17.18% |
| 2018-12-31 | $160.99 Million | $-48.66 Million | -0.302x | +15.13% |
| 2017-12-31 | $79.86 Million | $-28.44 Million | -0.356x | +20.10% |
| 2016-12-31 | $56.88 Million | $-25.35 Million | -0.446x | -104.14% |
| 2015-12-31 | $82.10 Million | $-17.93 Million | -0.218x | -29526.93% |
| 2014-12-31 | $-3.43 Million | $-2.55K | 0.001x | -99.62% |
| 2013-12-31 | $-123.96K | $-24.42K | 0.197x | -17.18% |
| 2012-12-31 | $-95.35K | $-22.68K | 0.238x | -15.92% |
| 2011-12-31 | $-68.03K | $-19.24K | 0.283x | -39.75% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more